openPR Logo
Press release

Myelodysplastic Syndrome Treatment Market Expected to Expand at a Steady CAGR through 2017- 2025

12-11-2017 12:05 PM CET | Health & Medicine

Press release from: Transparency Market Research

Myelodysplastic Syndrome Treatment Market Expected to Expand

Myelodysplastic syndrome (MDS) is a blood disorder caused due to the production of abnormal blood cells in bone marrow. Bone marrow failure leads to drop in the number of healthy blood cells in the body. In MDS, bone marrow does not produce healthy red blood cells, white blood cells, and/or platelets. Symptoms of MDS in the beginning are no specific than causes of pancytopenia i.e., deficiency of RBC, WBC and platelets. Therefore, the final diagnosis of MDS is done after examination of the cells of bone marrow. Bone marrow sample is taken from inside of a bone (usually the hip bone) and examined with a microscope using special stains to look for abnormal and immature cells. According to the American Cancer Society, over 13,000 new cases of MDS occur in the U.S. each year. According to the National Organization for Rare Disorders, 30% of patients with MDS can develop a form of blood cancer known as acute myeloid leukemia. Majority of patients diagnosed with MDS are aged between 65 and 70; however, MDS can affect people of any age and the risk of developing MDS increases with age.

Report Overview and TOC @ https://www.transparencymarketresearch.com/myelodysplastic-syndrome-treatment-market.html

The global myelodysplastic syndrome treatment market is driven by rise in the global geriatric population as MDS is most commonly found in this population and remains an incurable disease. Moreover, significant progress has been made in the diagnosis of MDS with the help of sequencing technologies. Chromosomal abnormalities can be identified in MDS patients with these technologies. These are useful for both diagnosis and prognosis in MDS patients. For instance, patients with chromosome 5q deletions are more likely to respond to lenalidomide. No new drugs have been approved for MDS by the U.S. Food and Drug Administration since 2006. Current available therapies can be efficacious, but are generally not curative. Some of the challenges in developing new treatments are the complexity and heterogeneity of MDS as a disease.

Request brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=34073

The global myelodysplastic syndrome treatment market can be segmented based on type of treatment and region. In terms of type of treatment, the market can be classified into supportive therapy, growth factors, chemotherapy (including hypomethylating agents), and stem cell transplant. Cytarabine, azacitidine, decitabine, and lenalidomide are the major drugs used during chemotherapy. Stem cell transplant is the only cure for MDS; however, majority of patients are not treated with stem cell transplant due to various factors such as high treatment cost, transplant-related deaths, and relapse rate at five years (as high as 40%). The chemotherapy segment is expected to hold major share of the global myelodysplastic syndrome treatment market due to larger application and less complications than other therapies such as stem cell transplant.

Geographically, the global myelodysplastic syndrome treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. North America is projected to dominate the global myelodysplastic syndrome market during the forecast period due to factors such as the rise in aging population and growing awareness about the disease among the population coupled with unmet medical needs in this region.

Key players operating in the global myelodysplastic syndrome treatment market are Celgene Corporation, Otsuka Holdings Co., Ltd., Sandoz, Inc., Dr. Reddy's Laboratories, Inc., Accord Healthcare Ltd., Mylan N.V., and Pfizer, Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Pre Book full report@ https://www.transparencymarketresearch.com/checkout.php?rep_id=34136

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact

Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
TMR Blog: http://www.theglobalhealthnews.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Myelodysplastic Syndrome Treatment Market Expected to Expand at a Steady CAGR through 2017- 2025 here

News-ID: 854317 • Views: 149

More Releases from Transparency Market Research

Meningitis Diagnostic Testing Market Outlook, Trend, Growth and Share Estimation …
Meningitis Diagnostic Testing Market: Overview The global meningitis diagnostic testing market was valued over US$ 105.5 Mn in 2016 and is projected to register cumulative annual growth rate (CAGR) of over 3.0% from 2017 to 2025, according to a new report published by Transparency Market Research (TMR) titled "Meningitis Diagnostic Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017-2025". The report suggests that rising demand for innovative
Metformin Hydrochloride API Market to Expand at a CAGR of ~5% from 2021 to 2031
Metformin Hydrochloride API Market: Introduction According to the report, the global metformin hydrochloride API market was valued at ~US$ 300 Mn in 2020 and is projected to expand at a CAGR of ~5% from 2021 to 2031. Metformin hydrochloride is primarily used in the treatment of diabetes. The prevalence of diabetes is expected to increase across the world due to change in lifestyle and factors such as malnutrition and genetic mutations.
Telehealth Market to Reach the Value of US$ 15 Bn by the End of 2028
Telehealth Market: Introduction According to the report, the global telehealth market was valued at US$ 7.8 Bn in 2020 and is projected to expand at a CAGR of 7% from 2021 to 2028. The global telehealth market has witnessed strong growth in the past few years. Telehealth is no longer an option, but a necessity due to the increasing dangers of COVID-19. Read Report Overview - https://www.transparencymarketresearch.com/telehealth-market.html The crisis presents an opportunity
Lyme Disease Treatment Market Growth Trends, Current Demand, and Development Rep …
Lyme Disease Treatment Market: Introduction According to the report, the global Lyme disease treatment market was valued at US$ 1.58 Bn in 2020 and is projected to expand at a CAGR of ~6% from 2021 to 2031. Increase in pet ownership, surge in awareness & adoption of veterinary care, and rise in healthcare expenditure on animals are anticipated to drive the global Lyme disease treatment market from 2021 to 2031.North America

All 5 Releases


More Releases for MDS

Healthcare M2M Market to See Huge Growth by 2025 | Athenahealth, McKesson, Amazi …
The Latest research study released by HTF MI “Global Healthcare M2M Market” with 100+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers, opportunities, market viewpoint and status. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Some of the Major Companies covered in this Research
Myeloidysplastic Syndromes (MDS) – Epidemiology Insights (2016-2028)
Myeloidysplastic syndromes (MDS) can be described as a group of hematologic malignancies, that occurr due to abnormality in blood-forming cells in the bone marrow. It is a rare blood cancer and can be mild, moderate or severe, in terms of severity. Download the sample report @ https://www.pharmaproff.com/request-sample/1162 This syndrome can be classified into three main types: MDS with single lineage dysplasia wherein a single type of blood cell appears abnormal; multilineage
Top Scenario: Healthcare CRM Market By Key Players: Allscripts, Cerner, e-MDs, C …
Qyresearchreports include new market research report Healthcare CRM to its huge collection of research reports. Healthcare CRM, also known as Healthcare Relationship Management, is a broadly used term for a Customer relationship management system In 2017, the global Healthcare CRM market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025. This report focuses on the global
Myelodysplastic Syndrome (MDS) Treatment Market Industry Forecast till 2025
Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more
Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size, Trends, Analysis …
An up-to-date research report has been disclosed by Market Research Hub highlighting the title “2018-2025 Report on Global and United States Myelodysplastic Syndrome (MDS) Therapeutics Market Status and Forecast, by Players, Types and Applications” which provides an outlook of current market growth as well as the expected forecast including Rate on Investment (ROI) together with growing CAGR near XX% during 2018-2025. The report studies myelodysplastic syndrome therapeutics in global market,
Myelodysplastic Syndrome (MDS) Treatment Market - Global Industry Insights 2025
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around